Hybrid multidimensional prostate MRI is 'a step in the right direction' for quantitative assessments

Using hybrid multidimensional MRI exams in lieu of multiparametric MRI for the assessment of prostate cancer could reduce interpretation times while increasing interobserver agreement. 

That’s according to a new analysis published in Radiology

“Hybrid multidimensional MRI (HM-MRI), a quantitative method, provides tissue percentage estimates based on MRI data by exploiting the interdependence of measured ADC and T2 values,” Grace H. Lee, from the Department of Radiology at the Sanford J. Grossman Center of Excellence in Prostate Imaging and Image Guided Therapy, and colleagues explained.  

HM-MRI provides data used to measure volume fractions of the lumen, epithelium, and stroma, as well as the ADC and T2 values relative to each volume fraction. Experts recently completed HM-MRI and multiparametric MRI (mpMRI) on 61 men with biopsy-confirmed prostate cancer to evaluate whether radiologist performance differed when interpreting each exam. 

Four radiologists participated in the analysis. The experts noted better per patient specificity in three out of four radiologists with HM-MRI and higher per patient AUC for the reader who was least experienced in interpreting the exam. Interobserver agreement was higher with HM-MRI and interpretation times were also shorter compared to mpMRI (73 seconds ± 43 vs 254 seconds ± 133). 

Due to the variability of PI-RADS categorization based on prostate MR imaging, Baris Turkbey, MD, from the Molecular Imaging Branch of the National Cancer Institute, National Institutes of Health, who wrote an editorial accompanying the study, suggests that the quantitative nature of HM-MRI analysis could provide more objective measures. 

“Quantitative prostate MRI methods have an important potential to enable objective, consistent performance for lesion detection and characterization tasks during radiology readouts,” Turkbey wrote. “The HM-MRI pulse sequence can further assist the current efforts for optimizing prostate MRI acquisition and interpretation.” 

The authors suggested that further studies are needed to validate their promising findings. 

View the study abstract here

Hannah murhphy headshot

In addition to her background in journalism, Hannah also has patient-facing experience in clinical settings, having spent more than 12 years working as a registered rad tech. She began covering the medical imaging industry for Innovate Healthcare in 2021.

Around the web

RBMA President Peter Moffatt discusses declining reimbursement rates, recruiting challenges and the role of artificial intelligence in transforming the industry.

Deepak Bhatt, MD, director of the Mount Sinai Fuster Heart Hospital and principal investigator of the TRANSFORM trial, explains an emerging technique for cardiac screening: combining coronary CT angiography with artificial intelligence for plaque analysis to create an approach similar to mammography.

A total of 16 cardiology practices from 12 states settled with the DOJ to resolve allegations they overbilled Medicare for imaging agents used to diagnose cardiovascular disease.